Specific Issues in the Design and Implementation of an Efficacy Trial for a Lyme Disease Vaccine

Meurice, François; Silberer, Dennis; Fu, Darrick; Krause, David S.

doi:10.1086/516167

Cited by 16 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most-studied B. burgdorferi membrane protein is outer surface protein A (OspA), a lipoprotein antigen expressed by borreliae in resting ticks and the most abundant protein expressed in vitro by most B. burgdorferi sensu lato isolates (2,32). Experimental OspA vaccines have demonstrated efficacy in several animal models (11,19,24,33), and OspA vaccines for human use are the subjects of current clinical evaluations (35,36,57).…”

mentioning

confidence: 99%

Active and Passive Immunity againstBorrelia burgdorferiDecorin Binding Protein A (DbpA) Protects against Infection

Hanson¹,

Cassatt²,

Guo

et al. 1998

Infect Immun

135

View full text Add to dashboard Cite

Borrelia burgdorferi, the spirochete that causes Lyme disease, binds decorin, a collagen-associated extracellular matrix proteoglycan found in the skin (the site of entry for the spirochete) and in many other tissues. Two borrelial adhesins that recognize this proteoglycan, decorin binding proteins A and B (DbpA and DbpB, respectively), have recently been identified. Infection of mice by low-dose B. burgdorferi challenge elicited antibodies against DbpA and DbpB that were sustained at high levels, suggesting that these antigens are expressed in vivo. Scanning immunoelectron microscopy showed that DbpA was surface accessible on intact borreliae. Passive administration of DbpA antiserum protected mice from infection following challenge with heterologous B. burgdorferi sensu stricto isolates, even when serum administration was delayed for up to 4 days after challenge. DbpA is the first antigen target identified that is capable of mediating immune resolution of early, localized B. burgdorferi infections. DbpA immunization also protected mice from B. burgdorferi challenge; DbpB immunization was much less effective. DbpA antiserum inhibited in vitro growth of many B. burgdorferi sensu lato isolates of diverse geographic, phylogenetic, and clinical origins. In combination, these findings support a role for DbpA in the immunoprophylaxis of Lyme disease and suggest that DbpA vaccines have the potential to eliminate early-stage B. burgdorferi infections.

show abstract

mentioning

confidence: 99%

Active and Passive Immunity againstBorrelia burgdorferiDecorin Binding Protein A (DbpA) Protects against Infection

Hanson¹,

Cassatt²,

Guo

et al. 1998

Infect Immun

135

View full text Add to dashboard Cite

show abstract

“…19,164,165 Vaccines consisting of recombinant OspA (LYMErix; GlaxoSmithKline, New York, NY) were granted approval in the United States in 1998. [166][167][168] They induced the recipient to make anti-Borrelia antibodies that would subsequently be taken into the tick's gut during feeding.…”

Section: Vaccinationmentioning

confidence: 99%

Lyme disease

Bhate

Schwartz

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…The first OspA vaccine to enter the American market was approved by the Food and Drug Administration (FDA) on 21 December, 1998 (10)(11)(12)(13). This monovalent vaccine consists of a full-length OspA (L-OspA) from one B6 strain (ZS7) expressed in an Escherichia colz ( 3 1 ) .…”

mentioning

confidence: 99%

Vaccination against Lyme borreliosis

Wahlberg¹

1999

Annals of Medicine

View full text Add to dashboard Cite

Lyme borreliosis is a worldwide family of tick-borne infections caused by the spirochete Borrelia burgdorferi sensu lato. It is the most common tick-borne human infection in the Western world. There are several subgroups of the spirochete. Two monovalent vaccines against this infection have been presented in the USA, both of which use the borrelial outer surface protein A (OspA) as antigen. The first of these vaccines has been released for general use. A European polyvalent vaccine using the antigen OspC is undergoing clinical trial in the Aland Islands in Finland. Lately, another antigen group, decorin-binding proteins (Dbp), has been considered for immunization purposes. A European vaccine must be effective against several subgroups of the borrelia spirochete, and this complicates the situation compared with that in the USA, where one spirochete subspecies dominates the scene.

show abstract

Specific Issues in the Design and Implementation of an Efficacy Trial for a Lyme Disease Vaccine

Cited by 16 publications

References 11 publications

Active and Passive Immunity againstBorrelia burgdorferiDecorin Binding Protein A (DbpA) Protects against Infection

Active and Passive Immunity againstBorrelia burgdorferiDecorin Binding Protein A (DbpA) Protects against Infection

Lyme disease

Vaccination against Lyme borreliosis

Contact Info

Product

Resources

About